Key result
AP-1 emerges as a key mechanistic regulator and potential therapeutic target in salt-sensitive hypertension.
Why the study?
Salt sensitivity of blood pressure is increasingly recognized as a complex immunoinflammatory process beyond fluid retention, with emerging evidence implicating transcriptional regulators such as AP-1 in renal, vascular, and immune crosstalk.
This review summarizes the crosstalk between renal, vascular, and immune signaling in salt sensitivity of blood pressure and identifies activator protein-1 (AP-1) as an emerging mechanistic regulator and potential therapeutic target.
AP-1 merits investigation as a therapeutic target in salt-sensitive hypertension; leaves open its clinical utility pending prospective trials.
Some individuals develop elevated blood pressure in response to increased dietary sodium intake, a phenotype known as salt sensitivity of blood pressure (SSBP). Our understanding of SSBP has expanded beyond the traditional view of sodium overload and fluid retention to recognize it as a complex immunoinflammatory process that contributes to progressive damage across multiple organs, particularly the kidneys and vasculature. High-salt exposure can activate immune cells, leading to increased production of reactive oxygen species (ROS), reduced nitric oxide (NO) bioavailability, and the release of pro-inflammatory cytokines. This persistent low-grade inflammation disrupts renal and vascular homeostasis and further exacerbates immune dysregulation. Growing evidence suggests that dysregulation of key transcriptional regulators, including hypoxia-inducible factor-1α (HIF-1α), mineralocorticoid receptor (MR), nuclear factor-κB (NF-κB), and activator protein-1 (AP-1), may play an important role in the development of SSBP by modulating immune activation, renal sodium handling, vascular dysfunction, and inflammatory signaling pathways. This review provides an overview of the current understanding of renal, vascular, and immune cell crosstalk in SSBP and highlights the emerging role of AP-1 as an important mechanistic regulator and potential therapeutic target.
No takes yet. Share an insight, caveat, or question.
Ahmad et al. (2026) conducted a review in Salt sensitivity of blood pressure (SSBP). Activator protein-1 (AP-1) / High dietary sodium intake was evaluated. Activator protein-1 (AP-1) is highlighted in this narrative review as an emerging mechanistic regulator and therapeutic target in salt sensitivity of blood pressure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: